“Global Vaccine Contract Manufacturing Market Set To Grow To $1.3bn By 2022″says Visiongain report.

19 July 2018
Pharma

Visiongain’ has launched a new pharma report Global Vaccine Contract Manufacturing Market Report 2018-2028 : Leading Countries, Technologies and Companies

The vaccine manufacturing technology and services market has experienced considerable growth over the past decade. Vaccines are a global healthcare success, currently driven by disease burden and the expanding global population. Strong growth will be seen in the therapeutic vaccines market, driven by development of vaccines for indications such as cancer. Our research suggests that demand and technological developments in this industry will drive changes in the methods and management of vaccine production. The global vaccine market will experience strong growth throughout the forecast period, as will that for outsourced vaccine manufacturing.

The lead analyst of the report commented “The transfer of vaccine technology is more difficult compared to other industries. This is the reason why the US and the EU5 have such a dominant market share of the vaccine contract manufacturing market. Vaccine manufacturing is highly technical with stringent regulatory and quality standards which have mainly kept it within regions which have the technology and regulatory framework to accommodate production.

Although off-shoring to lower costs is very popular for other industries, the vaccine contract manufacturing market in emerging markets will mainly show growth through domestic demands, at least in the first half of the forecast period, as emerging markets still grapples with international vaccine manufacturing practises and new technology platforms.”

Leading companies featured in the report include Baxter BioPharma Solutions, Boehringer Ingelheim, Catalent, Charles River Laboratories, IDT Biologika, Lonza, Meridian Life Science, Sigma Aldrich Fine Chemicals, Merck, Synco Bio Partners

Notes for Editors If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on + 44 (0) 20 7549 9987

About visiongain Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Direct-to-Patient Market Report 2021-2031

Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.

21 July 2021

Read

Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031

Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.

20 July 2021

Read

Visiongain Publishes Pharma Contract Sales Market Report 2021-2031

Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.

14 July 2021

Read

Visiongain Publishes Clinical Trial Supply and Logistics Market for Pharma 2021-2031

Digital innovation in clinical trials and renewed focus on home production will ensure a high growth market for supply chain optimisation.

12 July 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever